ONESOURCE news

• 27-Oct-2026 10:09:04

  ONESOURCE SPECIALTY PHARMA Q2 FY27 (CONS.) ; NET PROFIT UP 448.25% AT ₹57.48 CR (YOY), UP 129.96% (QOQ)

  REVENUE UP 37.39% AT ₹516.24 CR (YOY), UP 14.97% (QOQ) EBITDA UP 53.33% AT ₹163.29 CR (YOY), UP 32.38% (QOQ) MARGINS AT 31.63% VS 28.34% (YOY), 27.47% (QOQ)

• 27-Oct-2026 10:08:58

  ONESOURCE Q2 : CONS NET PROFIT UP 448% AT ₹57.5 CR (YOY), UP 130% (QOQ). STRONG (ON 1ST LOOK)

  Revenue up 37.4% at ₹516.2 Cr (YOY), up 15.0% (QOQ). Ebitda up 53.3% at ₹163.3 Cr (YOY), up 32.4% (QOQ); margins 31.6% v 28.3% (YOY), 27.5% (QOQ). Caution: Q2…

• 02-Jul-2026 16:23:23

  ONESOURCE SPECIALTY PHARMA: US-FDA INSPECTION AT BENGALURU FACILITY CONCLUDES WITH ONE OBSERVATION

  • A routine cGMP inspection was conducted by the USFDA at the Sterile Product Division facility in Bengaluru. • The inspection took place from June 22, 2026, t…

• 02-Jul-2026 15:05:45

  ONESOURCE SPECIALTY PHARMA : COMPLETION OF US-FDA INSPECTION

  • Routine cGMP inspection conducted by USFDA at Sterile Product Division facility in Bengaluru from June 22, 2026 to June 30, 2026. • The inspection concluded…

• 17-Jun-2026 13:05:22

  TENSHI PHARMACEUTICALS : CORPORATE FILING UNDER SEBI REGULATIONS

  • Declaration filed under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. • Promoter declares no encumbrance made…

← Back to feed